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Background
Primary bronchogenic carcinoma is a
major health problem with a generally
grim prognosis.1  It is the leading
cause of cancer deaths in both women
and men in the USA.2  The overall five-
year survival from lung cancer is 14%.
 For patients with local and regional
disease, the survival at five years is
48% and 18% respectively.  At the
time of diagnosis, only 15% of all lung
cancer patients will have local disease
and more than 55% will have distant
metastatic cancer.3
Ninety percent (90%) of patients
with lung cancer of all histological
types are current or former cigarette
smokers.1,4  Several established or
suspected human carcinogens are
present in the work environment and
it is estimated that 3% to 17% of lung
cancers are occupationally related.1,3
Mass screening for lung cancer
with chest radiology or sputum tests
for malignant cells have been discour-
aged for decades.5  Recently, there
has been some resurgence of interest
in screening for lung cancer, partly as
a result of the development of new
imaging techniques that enable the
detection of neoplasms at a much
earlier stage than was previously
possible.6,7,8
The treatment of choice for
bronchogenic carcinoma is surgical
resection, because it is the modality
that offers the greatest prospects for
a cure.9  A small beneficial effect on
survival can be demonstrated with
chemotherapy in patients with in-
operable lung cancer.10  Radiation
therapy is palliative and works best in
the management of bone, brain and
retinal metastases.11
Objectives
The primary objective was to deter-
mine the proportion of patients with
bronchogenic carcinoma amenable
to curative surgery at diagnosis.  The
secondary objectives were:
i. To compare the probability of ful-
filling the criteria for curative sur-
gery, at diagnosis, between the
two major histological types (i.e.
small vs. non-small cell) and the
two sexes (male and female); and
ii. To compare the duration of symp-
toms prior to diagnosis between
the operable and the inoperable
patients.
Patients and methods
The study was a record review of all
cases of histologically confirmed pri-
mary bronchogenic carcinoma, diag-
nosed over a two-year period (1999-
2000).  For the purposes of this study,
bronchogenic carcinoma refers to the
following major cell types: small cell
carcinoma, squamous cell carcinoma,
adenocarcinoma and large cell carci-
noma.  The last three histological types
were grouped together as non-small
cell lung cancers.  The data obtained
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from the records included the patients’
demographic data, tumour histology,
smoking habits, diagnostic proce-
dures, criteria used to exclude patients
from curative surgery and the duration
of symptoms prior to presentation.
The data were subjected to statis-
tical analysis, with a p value of =0.05
denoting statistically significant differ-
ences.  Fisher’s exact test was used
to compare the probability for curative
surgery for the following variables:
tumour histology, the sex of the patients
and the mean duration of symptoms
prior to diagnosis.
Results
Eighty-six patients were confirmed to
have primary bronchogenic carcinoma
during the study period.  This group
consisted of 74 (86%) males and 12
(14%) females.  The mean age of the
group was 57.9, ±10.8 years. Eighty-
five percent (85%) of the patients were
current tobacco users.  There were no
statistically significant differences be-
tween the ratios of smokers to non-
smokers amongst males and females
(P=0,079).  The mean duration of
symptoms prior to diagnosis was 3.9,
± 3.2 months. Ninety percent of the
cancers were of the non-small cell
variety.
Figure 1 indicates the diagnostic
procedures that were employed.
Of the 86 patients, only 13 (15%) were
deemed operable after the appropriate
evaluation.  There was no statistically
significant difference between the two
tumour types (small cell versus non-
small cell) with regard to the probability
of meeting the criteria for curative
surgery at diagnosis (P=1). About
12.2% of the male patients were
deemed operable, compared to 33.3%
of the females.  This difference was
not statistically significant (P=0.079).
 A comparison of the mean duration
of symptoms prior to diagnosis be-
tween the operable and inoperable
patients revealed no statistically sig-
n i f icant  d i f ferences (P=0.6) .
Thirty-four patients (39.5%) showed
evidence of metastatic disease at pres-
entation.  This consisted of 50% of the
small cell tumours and 38.5% of the
non-small cell variety. This difference
was not statistically significant
(P=0.707). Thirty-nine patients (45%)
were excluded from curative surgery
on the basis of advanced local disease
(T4) and poor lung function tests.
Discussion
The study suggests that the prognosis
of lung cancer remains grim.  Thera-
peutic advances have had little impact
on the outcome.  The burden of dis-
ease still falls disproportionately on
males. This may reflect the male-
dominated smoking habits in the com-
munity we serve. The majority of pa-
tients present within three to six months
after the onset of symptoms, yet 85%
were found to be inoperable.  This
suggests that symptoms in patients
with lung cancer develop late in the
disease.
Tobacco use remains an important
risk factor. The key intervention remains
prevention and broad efforts to help
people to stop smoking and to prevent
people from starting to smoke must
continue. Achieving this goal is
hampered by the strong addictive pow-
er of nicotine. The use of pharmaco-
therapy and, to a lesser extent, coun-
sell ing, provides considerable
assistance.12  Political courage to inhibit
indoor smoking to reduce second-hand
smoke inhalation is necessary. Restric-
tion of public smoking has persuaded
many smokers to quit smoking.13
Although efforts to reduce smoking
are crucial to the control of lung cancer,
the development of newer treatment
modalities for patients who currently
have the disease is also critical.  Re-
search aimed at finding better, inex-
pensive and readily available tech-
niques for the early detection of lung
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FIGURE 1: Bronchoscopy: washings, brushings and forceps biopsies
